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Abstract 
Mushroom has been used for thousand years in China and other Asian countries for health improvement 
and treatment of disease. A few decades ago, its main component beta-gluean was identified. Beta-
glueans are now known to have beneficial effects for the prevention and treatment of many diseases 
including eanccr, infectious disease, hyperlipidemia, diabetes, atherosclerosis and obesity. The effects are 
mediated by the different properties of beta-glucans such as immune stimulation and bile acid trapping. 
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EDITORIAL 
Recent Advance in the Studies of Beta-glucans for Cancer Therapy 
 
Mushroom has been used for thousand years in China and other Asian countries for health 
improvement and treatment of disease. A few decades ago, its main component beta-glucan was identified. 
Beta-glucans are now known to have beneficial effects for the prevention and treatment of many diseases 
including cancer, infectious disease, hyperlipidemia, diabetes, atherosclerosis and obesity [1-5]. The effects are 
mediated by the different properties of beta-glucans such as immune stimulation and bile acid trapping [I, 6]. 
In this special issue we have several experts to review the most recent advance in the field of the beta-glucan 
for cancer treatment. 
Cancer is a severe disease with increasing accidence due to the aging population and western life 
style (obesity). Cancer caused death is only second to heart disease, accounting for 13% of all human deaths 
[7]. Cancer is caused by both genetic defects such as mutations of genes in survival signalling pathways and 
environmental factors such as obesity [8,9]. These factors result in activation of multiple signal pathways 
necessary for cancer initiation and maintenance [10]. At present chemotherapy and radiotherapy are usually 
applied to those cancers that cannot be removed by surgical procedure. However, the treatment outcomes are 
not satisfactory. Inhibition of intracellular signalling pathways, which is termed targeted therapy, is promising 
[11,12]. Multiple signalling pathways have been studied and many inhibitors have been developed to target 
these pathways such as Src/PI3K1Akt/mTOR, HGF/met, VEGF, EGFR, and MAPK [13-19]. Individualised targeted 
therapy may be needed as each patient may have different profile of altered signalling pathways [20]. Beta-
glucans can be used for stimulating immune system. The immunotherapy via manipulation of immune system 
has also been applied for the treatment of cancer which facilitates the elimination of weaken cancer cells by 
chemotherapy or targeted therapy [21-25]. Different components of both innate and adaptive immune system 
may be manipulated such as antibody, T-cell, killer cells, dendritic cells and cytokines [26-29]. Beta-glucans can 
stimulate both innate and adaptive immune responses and could be used for immunotherapy for cancer 
treatment [I]. 
In this special issue Professor Van has introduced the effect of beta-glucan on dendritic cells (DCs), 
which are antigen-presenting cells. These cells bridge innate immunity and adaptive immunity. The molecular 
mechanisms for beta-glucan to stimulate DCs are well elucidated. Beta-glucans are recognised by pattern 
recognition receptors on DCs and activate these receptors to increase DC functions. Activation of DCs 
can result in adaptive immune responses such as CD8+ CTLs. Professor Van emphasises several receptors 
including CR3, LaeCer, SRs, Dectin-I in DCs and their downstream signals in the development of DCs and the 
secretion of cytokines. As various beta-glucans have different effects, it is proposed that a certain beta-glucan 
to be tested at a specific cancer to form personalized medicine. 
After extensive studies of beta-glucans from mushroom in laboratory test and animal models, many 
clinical trials have been performed. Professor Aleem's article focuses on the use of beta-glucans on patients. 
After providing the interesting history of the medicinal implications of mushroom beta-glucans, she reviewed 
the clinical trials of several beta-glucans including letinan, Maitake D- and MD-fractions, extracts from Agaricus 
sp., polysaccharide-K, and Schizophyllan. She also discussed combined consumption of mushroom with other 
phytochemicals. Interestingly several mechanisms other than immune stimulation effect such as direct effects 
of beta-glucans on cancer cells, on estrogen receptors, and P450 enzyme aromatase were also summarised. 
Gastric cancer is the fourth and fifth most common cancer in men and women respectively and it is 
the third and fifth most common cause of cancer-related death in men and women according to most recent 
statistics [7]. Lentinan has been used clinically extensively for the treatment of gastric cancer. In his article, 
Professor Ina reviewed mechanisms for the treatment effect of letinan in gastric cancer and introduced how 
lentinan is used in combination with fluoropyrimidine to increase survival time of patients. 
Metastasis is a major cause for cancer-related death [8, 30-33]. Professor Lee introduced the 
application ofbeta-glucans for the treatment of metastatic cancer. The effects of different beta-glucans 
including Grifolan, Lentinan, Agaricus Blazei, Schizophyllan, Sclerotiorum and yeast on metastatic models in 
animals are summarised. He also discussed the combinatorial therapies with irradiation, cytokines (INF-gamma 
and 11-2), chemotherapeutic agent fluropyridine in models of lung, liver and colon cancers. He pointed out 
that data from clinical trials are scarce and contradictory and further investigation is needed. 
Most of research in beta-glucan has used mushroom extracts and purity ofbeta-glucans has been a 
major problem in the research of beta-glucans. Other components of mushroom may also have anti-cancer 
effect. This may interfere with the evaluation of beta-glucan anti-cancer effect. Professor Vetevicka discussed 
the application of synthesised oligo-saccharides for cancer treatment. 
Beta-glucans are usually used in combination with other chemotherapeutic agents. Future work may 
further optimise the incorporation of beta-glucans in cancer treatment regimes. The studies of beta-glucans 
may be carried out in cancer stem cells as these cells are most related to cancer metastasis and drug resistance 
[34]. 
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